FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2913282972> ?p ?o ?g. }

• W2913282972 abstract "Background: With the increasing success of immune checkpoint blockades for cancer treatment, we increasingly need well-characterized preclinical models. Syngeneic mice models (with a fully competent immune system) have advantages that they are easily established and cost less, though they do not reflect genetic complexity of human tumors. We evaluated feasibility of syngeneic mice models of breast cancer by analyzing efficacy of immune checkpoint blockade and dynamic change of tumor immune microenvironment. Methods: We used syngeneic mice model of JC, 4T1, and EMT6 cells, which are all murine triple negative breast cancer in BALB/c mice. At the time when subcutaneous tumors reach at 50˜100mm^3, each mice models were divided into 2 groups for treatment versus no-treatment control. In the treatment group, mice version of anti-PD-1 antibody was intraperitoneally injected (q 3 days, x 6). Anti-tumor efficacy was monitored by measuring tumor volume. 9Tumor response9 was defined as a case with tumor volume less than that of control group by a standard error at a determined time point. Immune microenvironment was evaluated by measuring serum cytokines (IL-2, IL-6, IL-10, IFNγ, and TNFα) with legendplex and immune cells (CD3, CD4, CD8, CD56, and FOXP3) of peripheral blood with FACS before injection of PD-1 blockade, after 1st injection, and when euthanized. Tumor-infiltrating immune cells were evaluated with FACS, when euthanized. Results: The tumor response rate to PD-1 blockade was highest in the 4T1 model (54.5%, 6/11) compared to JC model (40%, 4/10) or EMT6 model (36.4%, 4/11). Bleeding 3 times and tumor obtainment when euthanized in each mouse were feasible for profiling of cytokines and immune cells. Although before treatment with PD-1 blockade, CD3+T cells in peripheral blood were slightly lower in 4T1 model (18.3±8.1%) than JC model (24.6±4.7%) or EMT6 model (27.9±6.3%), after injection of one dose of PD-1 blockade, CD3+T cells increased 1.5 times in 4T1 model (18.3% to 27.3%), whereas those CD3+T cells decreased slightly in JC model and EMT6 model. Dynamic changes were not observed in other subsets of peripheral immune cells in all 3 models. Serum TNFα (with statistical significance) and IFNγ (with borderline significance) were higher in responders than in non-responders or no-treatment control. Conclusions: Syngeneic mice models of breast cancer were feasible to investigate immune checkpoint blockades and monitor dynamic change of immune microenvironment. In this regard, such models may be used to evaluate immune checkpoint blockade-based combination therapy as well. Citation Format: Moon YW, Park N, Hur J, Pandey K, Cho YB, Kim SK, Lee SA, Son GW, Jo JM, An H-J. Feasibility of sygeneic mice models of breast cancer for research of immune checkpoint blockades [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-06-23." @default.
• W2913282972 created "2019-02-21" @default.
• W2913282972 creator A5003066179 @default.
• W2913282972 creator A5013823756 @default.
• W2913282972 creator A5015881062 @default.
• W2913282972 creator A5025694812 @default.
• W2913282972 creator A5038758275 @default.
• W2913282972 creator A5042364992 @default.
• W2913282972 creator A5044048872 @default.
• W2913282972 creator A5046343631 @default.
• W2913282972 creator A5058060317 @default.
• W2913282972 creator A5083718913 @default.
• W2913282972 date "2019-02-15" @default.
• W2913282972 modified "2023-10-14" @default.
• W2913282972 title "Abstract P4-06-23: Feasibility of sygeneic mice models of breast cancer for research of immune checkpoint blockades" @default.
• W2913282972 doi "https://doi.org/10.1158/1538-7445.sabcs18-p4-06-23" @default.
• W2913282972 hasPublicationYear "2019" @default.
• W2913282972 type Work @default.
• W2913282972 sameAs 2913282972 @default.
• W2913282972 citedByCount "0" @default.
• W2913282972 crossrefType "proceedings-article" @default.
• W2913282972 hasAuthorship W2913282972A5003066179 @default.
• W2913282972 hasAuthorship W2913282972A5013823756 @default.
• W2913282972 hasAuthorship W2913282972A5015881062 @default.
• W2913282972 hasAuthorship W2913282972A5025694812 @default.
• W2913282972 hasAuthorship W2913282972A5038758275 @default.
• W2913282972 hasAuthorship W2913282972A5042364992 @default.
• W2913282972 hasAuthorship W2913282972A5044048872 @default.
• W2913282972 hasAuthorship W2913282972A5046343631 @default.
• W2913282972 hasAuthorship W2913282972A5058060317 @default.
• W2913282972 hasAuthorship W2913282972A5083718913 @default.
• W2913282972 hasConcept C121608353 @default.
• W2913282972 hasConcept C126322002 @default.
• W2913282972 hasConcept C159654299 @default.
• W2913282972 hasConcept C167672396 @default.
• W2913282972 hasConcept C170493617 @default.
• W2913282972 hasConcept C203014093 @default.
• W2913282972 hasConcept C2776090121 @default.
• W2913282972 hasConcept C2776107976 @default.
• W2913282972 hasConcept C2777701055 @default.
• W2913282972 hasConcept C2778326572 @default.
• W2913282972 hasConcept C2778468042 @default.
• W2913282972 hasConcept C2779727006 @default.
• W2913282972 hasConcept C2780851360 @default.
• W2913282972 hasConcept C502942594 @default.
• W2913282972 hasConcept C530470458 @default.
• W2913282972 hasConcept C71924100 @default.
• W2913282972 hasConcept C8891405 @default.
• W2913282972 hasConceptScore W2913282972C121608353 @default.
• W2913282972 hasConceptScore W2913282972C126322002 @default.
• W2913282972 hasConceptScore W2913282972C159654299 @default.
• W2913282972 hasConceptScore W2913282972C167672396 @default.
• W2913282972 hasConceptScore W2913282972C170493617 @default.
• W2913282972 hasConceptScore W2913282972C203014093 @default.
• W2913282972 hasConceptScore W2913282972C2776090121 @default.
• W2913282972 hasConceptScore W2913282972C2776107976 @default.
• W2913282972 hasConceptScore W2913282972C2777701055 @default.
• W2913282972 hasConceptScore W2913282972C2778326572 @default.
• W2913282972 hasConceptScore W2913282972C2778468042 @default.
• W2913282972 hasConceptScore W2913282972C2779727006 @default.
• W2913282972 hasConceptScore W2913282972C2780851360 @default.
• W2913282972 hasConceptScore W2913282972C502942594 @default.
• W2913282972 hasConceptScore W2913282972C530470458 @default.
• W2913282972 hasConceptScore W2913282972C71924100 @default.
• W2913282972 hasConceptScore W2913282972C8891405 @default.
• W2913282972 hasLocation W29132829721 @default.
• W2913282972 hasOpenAccess W2913282972 @default.
• W2913282972 hasPrimaryLocation W29132829721 @default.
• W2913282972 hasRelatedWork W1495108757 @default.
• W2913282972 hasRelatedWork W2322919275 @default.
• W2913282972 hasRelatedWork W2785888115 @default.
• W2913282972 hasRelatedWork W2895289354 @default.
• W2913282972 hasRelatedWork W2913282972 @default.
• W2913282972 hasRelatedWork W2954928134 @default.
• W2913282972 hasRelatedWork W3110073904 @default.
• W2913282972 hasRelatedWork W3204309362 @default.
• W2913282972 hasRelatedWork W4206466482 @default.
• W2913282972 hasRelatedWork W4283361025 @default.
• W2913282972 isParatext "false" @default.
• W2913282972 isRetracted "false" @default.
• W2913282972 magId "2913282972" @default.
• W2913282972 workType "article" @default.